ImmusoftProgramming Cures
Immusoft is developing a cutting edge approach to sustained delivery of protein therapeutics using a patient’s own cells. The approach is called Immune System Programming (ISP™). ISP entails collecting a type of the patient’s immune cells, called B cells. In response to immune stimulation, B cells can turn into a biofactory state known as a plasma cell. Plasma cells manufacture and secrete thousands of antibodies per second. We harness this biofactory capability of the plasma cell by programming B cells to produce a given protein therapeutics.
Once we have programmed the B cells we expand the number of them many times and differentiate them into plasma cells (or, stated simply, coax them into the biofactory state) that produce massive amounts of our therapeutic protein. Thereafter we infuse the ISP™ programmed cells back into the same patient, where they take up residence and produce therapeutic proteins for extended periods of time.
This chart provides an overview of our ground breaking technology. Click below for a fuller explanation.
Dr. McIvor, Chief Development Officer, to present on the Sleeping Beauty-Engineered B Lymphocytes ISP™ platform
Seattle, Wash.–(BUSINESS WIRE) –July17,2019–Immusoft Corporation, a Seattle-Wash.-based, leading cell therapy company, today announced the appointment of Robert Hayes, Ph.D., as Chief Scientific Officer. With nearly two decades of biologics discovery and development experience, Dr. Hayes will lead Immusoft’s preclinical research and spearhead the near-term advancement…
Seattle, Wash.–(BUSINESS WIRE) –January 3, 2019– Immusoft Corporation, a Seattle-Wash.-based cell therapy company, announced today it has held the final closing in its $20 million oversubscribed Series B financing. Immusoft plans to use the proceeds from this financing to advance ISP-001 (iduronicrin genleukocel-T) through Phase I/II…
